Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Ipca Laboratories Limited

Ipca Laboratories is involved in the development and manufacture of active pharmaceutical ingredients and formulations, catering to healthcare needs.

NSE:IPCALAB

Ipca Laboratories

Last Close

1,591.35

25/11 09:40

Market Cap

310.50B

Beta: 0.15

Volume Today

587.38K

Avg: 675.74K

PE Ratio

58.44

PFCF: -

Dividend Yield

0.18%

Payout:0%

Financials Not Available